Antihypertensive activity occurs by the depletion of tissue stores of catecholamines from peripheral sites. This class of agents generally has been replaced by other antihypertensive agents that are safer and more effective. This drug was approved by the FDA in 1956. Depression, active peptic ulcer, ulcerative colitis, electroconvulsive therapy, hypersensitivity to tartrazines. Exacerbation of parkinson signs and symptoms.
Concurrent use can result in excessive excitation, hypertension, and sympathetic response.
Initially, 0.5 mg PO bid. Increase gradually if necessary. Maintenance dose is usually 0.25-0.5 mg daily. Parkinsn's List Drug Database Index Parkinsn's Archive Treasures Page John Cottingham is the webmaster of this site.